Welcome to our dedicated page for Keros Therapeutics SEC filings (Ticker: KROS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Keros Therapeutics, Inc. (Nasdaq: KROS) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Keros’ clinical programs, capital allocation decisions, governance changes and financial condition.
As a clinical-stage biopharmaceutical company focused on TGF-ß pathway therapeutics, Keros uses its SEC filings to report material events related to its lead product candidate KER-065 and its most advanced candidate elritercept. Form 8-K reports have covered topics such as additional clinical data from a Phase 1 trial of KER-065, U.S. Food and Drug Administration Orphan Drug designation for KER-065 in Duchenne muscular dystrophy, and corporate updates regarding the prioritization of KER-065 and discontinuation of internal development of cibotercept (KER-012).
Filings also document Keros’ capital return program and share repurchase activity. Recent 8-Ks describe stock purchase agreements with entities affiliated with ADAR1 Capital Management and Pontifax Venture Capital, the planned and completed cash tender offer to repurchase a substantial number of shares of common stock at a fixed price, and related governance changes. Other reports furnish quarterly financial results, including revenue from a global license agreement with Takeda Pharmaceuticals U.S.A., Inc. related to elritercept, research and development spending and cash and cash equivalents.
On this page, users can review real-time updates as new KROS filings are posted to EDGAR, including Forms 8-K, 10-Q and 10-K when available, as well as exhibits such as press releases and corporate presentations. Stock Titan’s AI-powered tools summarize lengthy filings, highlight key sections and help explain complex topics like capital return structures, executive employment agreements and risk factor disclosures in more accessible language.
For those analyzing Keros’ development strategy, financial runway, licensing arrangements or governance, the SEC filings page serves as a primary source of company-sanctioned information. It allows investors and researchers to trace how Keros reports progress on its TGF-ß–focused pipeline, documents material agreements and communicates significant corporate events over time.
Keros Therapeutics (KROS) — Form 4 filing: Pontifax-affiliated funds reported open market sales of common stock on 10/15/2025 at $17.75 per share. Reported disposals include 2,284,612 shares by Pontifax (Israel) IV, L.P.; 1,121,045 by Pontifax (Cayman) IV, L.P.; 1,226,412 by Pontifax (China) IV, L.P.; and 155,262 by Pontifax Late Stage Fund, L.P. Each fund reported 0 shares beneficially owned following the transactions.
The filing lists indirect ownership through Pontifax entities and indicates that Tomer Kariv and Ran Nussbaum each reported 5,250 shares indirectly. The footnotes state that, in connection with a Stock Purchase Agreement dated October 15, 2025 and their resignations from the board, the issuer accelerated the vesting of restricted stock units and certain options previously reported for Messrs. Kariv and Nussbaum.
Keros Therapeutics entered definitive agreements to repurchase 10,176,595 shares from affiliates of ADAR1 Capital Management and Pontifax Venture Capital at $17.75 per share, for an aggregate purchase price of approximately $181 million. The company also announced its intention to commence a tender offer to all stockholders, at $17.75 per share, to complete its previously announced plan to return $375.0 million of excess capital, subject to market conditions.
The company expects to complete the negotiated repurchases on or about October 15, 2025 and intends to launch the tender offer by the end of October 2025. As of September 30, 2025, cash and cash equivalents were preliminarily estimated at $693.5 million. Following the Pontifax agreement, directors Tomer Kariv and Ran Nussbaum resigned, and Jean‑Jacques Bienaimé was appointed Chair of the Nominating and Corporate Governance Committee. The repurchase parties agreed to standstill, voting commitments, and mutual non‑disparagement through the conclusion of the 2028 annual meeting certification.
Keros Therapeutics entered agreements to repurchase all shares held by ADAR1 Capital Management and Pontifax Venture Capital, totaling 10,176,595 shares of common stock at $17.75 per share, for an aggregate purchase price of approximately $181 million. The company expects to complete these repurchases on or about October 15, 2025 and then intends to commence a tender offer to all holders at $17.75 per share to complete its previously announced plan to return $375.0 million to stockholders, subject to market conditions.
As of September 30, 2025, cash and cash equivalents are expected to be approximately $693.5 million (preliminary and unaudited). The ADAR1 parties beneficially owned 5,389,264 shares (about 13.3%) and the Pontifax parties 4,787,331 shares (about 11.8%) as of October 14, 2025. In connection with the Pontifax agreement, Tomer Kariv and Ran Nussbaum resigned from the board, and Jean‑Jacques Bienaimé was appointed Chair of the Nominating and Corporate Governance Committee. The repurchase parties agreed to standstill and voting commitments through the final certification of the 2028 annual meeting results, along with mutual non‑disparagement.
Keros Therapeutics (KROS): Section 16 filing reports insider sales. On 10/15/2025, reporting persons linked to ADAR1 disclosed sales of Keros common stock at $17.75 per share. The transactions were reported as indirect holdings through affiliated entities.
Reported sales included 4,391,237 shares by ADAR1 Partners, LP; 254,669 shares by ADAR1 SPV I, LP; and 743,358 shares by Spearhead Insurance Solutions IDF, LLC. For each line item, the amount of securities beneficially owned following the transactions was listed as 0, with ownership form marked as indirect.
The filing notes that ADAR1 Capital Management, LLC (investment manager/sub‑advisor), ADAR1 Capital Management GP, LLC (general partner), and Daniel Schneeberger (manager) may be deemed to indirectly beneficially own the securities, and each disclaims beneficial ownership except to the extent of pecuniary interest.
Keros Therapeutics, Inc. reported that it issued a press release on September 8, 2025 describing additional clinical data from its Phase 1 trial of KER-065 in healthy male volunteers. The company presented these data at the American Society of Bone and Mineral Research 2025 Annual Meeting held on September 6, 2025.
The Form 8-K notes that the press release is furnished as Exhibit 99.1 and is incorporated by reference, except for the quoted statements. No financial results or transaction details are included in this report, which focuses on the disclosure of new early-stage clinical information about KER-065.
Keros Therapeutics, Inc. filed a current report to share that its President and Chief Executive Officer, Jasbir Seehra, will speak at two upcoming investor conferences. On September 4, 2025, he is scheduled for a fireside chat at the 2025 Wells Fargo Healthcare Conference at 2:15 p.m. Eastern time. On September 9, 2025, he will give a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference at 12:00 p.m. Eastern time.
The company disclosed this through a press release dated August 28, 2025, which is furnished as Exhibit 99.1. The information under this item is being treated as “furnished” rather than “filed” under the Exchange Act, which limits its use for certain legal liability purposes and incorporation into other securities filings unless specifically referenced.
ADAR1 Capital Management and related entities report beneficial ownership of 5,389,264 shares (13.27%) of Keros Therapeutics (KROS). The Schedule 13D/A (Amendment No.4) states ADAR1 issued an August 21, 2025 press release and open letter criticizing the Board's refusal to engage on strategy, capital allocation and Board refreshment and said it will seek to elect new directors at the next annual meeting if the Board continues to refuse engagement. The filing notes no transactions in the past 60 days, the reporting persons no longer hold previously reported long and short put positions, and the ownership percentage is based on 40,615,414 shares outstanding as of July 31, 2025.
Keros Therapeutics reported that the U.S. Food and Drug Administration granted Orphan Drug designation to its investigational therapy KER-065 for treating Duchenne muscular dystrophy. This special status is reserved for drugs targeting rare, serious conditions and can provide regulatory and economic incentives to support development. The company disclosed this update through a press release, which is attached as an exhibit and incorporated by reference.
Keros Therapeutics insider Lorena Raquel Lerner, identified as the company’s Chief Science Officer, reports beneficial ownership of 35,000 restricted stock units and employee stock options covering 41,379 underlying shares. The RSUs vest in three tranches (33% on Feb 17, 2026; 34% on Aug 15, 2026; 33% on Feb 16, 2027). Listed options have exercise prices of $43.99, $54.38 and $56.18 with multi-year vesting schedules.
Esther Cho, SVP and General Counsel of Keros Therapeutics, Inc. (KROS), reported initial beneficial ownership on Form 3 for an event dated 08/06/2025. She directly holds 44,000 shares (RSUs) and beneficially owns employee stock options exercisable into 165,968 common shares across five option grants with exercise prices ranging from $29.02 to $70.93.
FAQ
What is the current stock price of Keros Therapeutics (KROS)?
What is the market cap of Keros Therapeutics (KROS)?
